In this study we investigated whether neoplastic transformation occurring in Ph-negative Myeloproliferative Neoplasms (MPN) could involve also the endothelial cell compartment.
Abstract
In this study we investigated whether neoplastic transformation occurring in Ph-negative Myeloproliferative Neoplasms (MPN) could involve also the endothelial cell compartment.
We evaluated the level of endothelial colony forming cells (ECFC) in 42 patients (15 with polycythemia vera, 12 with essential thrombocythemia and 15 with primary myelofibrosis (PMF).
All patients had one or more molecular abnormality (JAK2 V617F or MPL W515K mutations, SOCS genes hypermethylation, clonal pattern of growth) detectable in their granulocytes. The growth of colonies was obtained in 22 patients and, among them, patients with PMF exhibited the highest level of ECFC. We found that ECFC exhibited no molecular abnormalities in12 patients, had SOCS gene hypermethylation and were polyclonal at the HUMARA assay in 5 patients, and resulted
JAK2
V617F mutated and clonal in 5 additional patients, all experiencing thrombotic complications.
On the whole, patients with altered ECFC required antiproliferative therapy more frequently than patients with normal ECFC. Moreover JAK2 V617F positive ECFC showed a STAT5 and STAT3 phosphorylation rate higher than ECFC isolated from healthy individuals and from MPN patients without molecular abnormalities. Finally, JAK2 V617F positive ECFC exhibited a high proficiency to adhere to normal mononuclear cells. This study highlights a novel mechanism underlying the thrombophilia observed in MPN.
Introduction
During the embryonic development hematopoietic and endothelial cells arise from a mesoderm-derived common precursor called hemangioblast. 1 The existence of an exceedingly rare hemangioblast progenitor has been demonstrated also in the postnatal life in the CD34/KDR positive cell subset. 2 This cell appears to be endowed with long-term proliferative potential and with both hematopoietic and endothelial differentiation capacity. 2 Since Ph-negative myeloproliferative neoplasms (MPN) show a high incidence of vascular complications 3 and an endothelial cell dysfunction has been evidenced in patients with Polycythemia Vera (PV), 4 several studies explored the possibility that the neoplastic transformation in MPN could involve also the endothelial cell compartment. [5] [6] [7] [8] [9] On the whole, studies based on the in vitro assays for endothelial progenitors have identified JAK2 V617F mutation or specific chromosome alterations only in endothelial progenitors derived from the hematopoietic lineage (the so called colony forming unitendothelial cells, CFU-EC), [5] [6] [7] whilst the true endothelial colony forming cells, (ECFC) do not harbor genetic abnormalities. 6, 7 In conflict with these findings, Sozer et al. found that endothelial cells isolated by micro-dissection from liver biopsies of PV patients with Budd-Chiari Syndrome (BCS) exhibit the JAK2 V617F mutation. 8 In reality, granulocytes isolated from patients with MPN can harbor several genetic defects in addition to the JAK2 V617F mutation, like the hypermethylation of Suppressor of Cytokine Signaling (SOCS) genes [10] [11] [12] or the presence of a clonal pattern of proliferation. 13 Importantly, in some circumstances, these defects can be detected in the absence 10, 11 or even before the neoplastic clone acquired the JAK2 V617F mutation. [14] [15] [16] For these reasons, in this study we investigated endothelial progenitor cells isolated from patients with MPN for a large panel of molecular markers. Our results evidenced that a subset of MPN patients shows in endothelial progenitors the same molecular signatures detectable in the hematopoietic clone.
Moreover, we found that the presence of JAK2 V617F mutation into endothelial progenitors is associated with the hyper-phosphorylation of STAT-3 (pSTAT-3) and , with an were counted as CFU-EC. For the ECFC colonies, mononuclear cells were suspended in EGM-2 media (EGM-2 Bulletkit, Lonza, Milan) on human fibronectin coated 6-well dishes. At day 2 nonadherent cells were discharged and residual adherent cells were grown in EGM-2 medium for 28 days, with medium replacement every 3 days. Well-circumscribed monolayer of cobblestoneappearing cells growing from day 9 to day 28 were counted as ECFC and singly recovered. The true hematological or endothelial nature of CFU-EC and ECFC was investigated by RT-PCR the expression of von-Willebrand factor (vWF), CD146, CD45, KDR, CD11b and CD115, as described. 9 The following primers were used: KDR: forward Representative CFU-EC and ECFC colonies and their RT-PCR characterization are shown in Figure   1 . Capillary formation assay was performed as described 19, 20 24 in all JAK2 V617F negative patients. The presence or the absence of the JAK2 mutation were confirmed by direct sequencing using the external primers described in the method of Baxter et al. 21 The presence of MPL mutations (MPL W515L and MPL
W515K
) was investigated by sequencing, using the same primers and PCR conditions previously described.
23

JAK2
V617F allele burden. The mutant allele burden was measured by a quantitative real time (QRT)-PCR assay following the methods previously reported. 25 All samples were analyzed in triplicate.
Human Androgen Receptor Analysis (HUMARA). The clonal pattern of growth was assessed by the
HUMARA polymorphism assay and by the HUMARA methylation-specific PCR (MS-PCR) in granulocytes and in pooled ECFCs isolated from female patients, as previously described. 22 Tlymphocytes were used as control. Briefly, 1 μg of DNA was incubated with and without 20 units of HpaII (New England Biolabs, Beverly, MA) at 37°C for 12 hours. After 10 minutes of incubation at 95°C, 3 µl of all samples were amplified with specific primers as previously described. 22 Results obtained by the HUMARA polymorphism assay were confirmed by HUMARA methylation-specific PCR analysis. Briefly, after treatment of 1 μg of DNA with sodium bisulphate, purification and desulfonation with sodium hydroxide, DNA was amplified with specific primers for methylated and unmethylated HUMARA gene. 23 PCR amplification and correction of the ratio of peaks for an appropriate X-inactivation pattern were performed by using the ABI PRISM 3100Avant Genetic
Analyzer and GeneMapper ID software (Applied Byosystems, Foster City, California, USA).
Methylation specific-PCR for SOCS-1, SOCS-2 and SOCS-3 CpG islands. Methylation status of
SOCS-1, SOCS-2 and SOCS-3 CpG islands was investigated by methylation-specific PCR (MS-
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 8 PCR) as described. 11 One μg of genomic DNA was subjected to bisulphite modification using EpiTect Bisulphite kit (QIAGEN, Hilden, Germany), according to the manufacturer's protocol and then amplified in a mixture containing PCR buffer containing primers (20 pM each) and 0.25 U GoTaq polymerase (Promega, Milan, Italy). 11 PCR products were electrophoresed in a 2.5%
agarose gel, stained with ethidium bromide and visualized under UV light. DNA isolate from normal lymphocytes, hypermethylated with SssI methyltransferase (New England Biolabs) and subsequently modified with bisulphite, was used as unmethylated and methylated controls; water was used as negative control; unmodified DNA was used as internal control of MS-PCR. All samples resulted methylated were subjected to sequencing, either directly or after sub-cloning.
11
Briefly, The PCR products were cloned into a pGEM-T easy vector system (Promega) using JM109
high efficiency competent cells. Five randomly picked clones were sequenced on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
Western blot analysis of pSTAT-3 and pSTAT-5.
In selected experiments, ECFCs recovered in each patient were pooled and evaluated for the expression of pSTAT-3 and pSTAT-5, as described. 22 Briefly, after cell lysis, supernatant proteins were recovered, dissolved in SDS sample buffer, boiled for 5 minutes and then separated on SDS polyacrilamide gel electrophoresis (SDS-PAGE). Gels were blotted with transfer buffer directly on pure nitrocellulose membrane (Bio-Rad) at 330 mA for 1 hour. After not specific binding sites blocking, blots were probed with an anti-pSTAT-3 (1:500, Santa Cruz Biotechnology, Heidelberg, Germany), anti-pSTAT-5 (1:500, BD Biosciences, Milan, Italy) and anti-actin (Ab-5, 1:5000, BD Biosciences) mouse monoclonal antibodies. Blots were the incubated with goat anti-mouse HRP conjugated antiserum (1:1000, BD Biosciences) , covered with ECL solutions for 1 minutes (western blotting analysis system) (GE Healthcare, United Kingdom) and exposed to Kodak XAR-5 x-ray film (Kodak, Rochester, USA). Precipitates were subjected to densitometric analysis using the Gel-Doc 2000 Quantity One program (Biorad), after normalization with the actin intensity. (Table 3) . Ten patients were females and could be evaluated also for the HUMARA assay. According to their hematological signature and confirming previous findings from other groups 6, 7 , we found that CFU-EC in these patients always exhibited the same molecular markers as granulocytes (data not shown). In contrast, the behavior of ECFC was variable and we could identify three groups of patients (Table 3) .On the whole, the mean number of assayed ECFC for each patient was 7 in the first group, 5 in the second group and 9 in the third group (p = 0.14). The first group included 12 patients which had normal ECFC, lacking those MPN molecular alterations observed in the respective granulocyte samples (Table 3 ). In three of these patients, we evidenced that the pattern of growth of ECFC was polyclonal at the HUMARA
Results
CFU-EC and ECFC recovery.
assay. Conversely, ECFC progenitors obtained from the remaining 10 patients exhibited molecular myeloproliferative signatures. In particular, ECFC collected from 5 patients (13 to 17, Table 3) showed a pattern of SOCS gene hypermethylation overlapping that found in the respective granulocytes: in particular SOCS-1 gene was involved in 3 cases (patients 14, 15 and 17, Table 3 ), SOCS -2 in 1 case (patient 13, Table 3 ) and both SOCSC-1 and SOCS-2 in 1 case (patient 16, Table   3 ). Interestingly, although 3 of them were JAK2 V61F positive and 1 was MPL K515L positive, these mutations were not detected in ECFC. In one case (patient 13, Table 3 ) we found ECFC both unmethylated (1 colony) and methylated (4 colonies). When these colonies were pooled and assayed for the HUMARA, they appeared polyclonal. Indeed, these observations evidenced that in this patient normal endothelial progenitors may persist and circulate. Finally, the third group included 5 patients exhibiting the growth of JAK2 V61F positive ECFC (patients 18 to 22, Table 3 ).
All the examined ECFC were JAK2 V61F positive and no JAK2 wild type colonies were observed.
The burden of JAK2 V61F allele in each examined ECFC was variable from colony to colony, and ranged from 30 to 74 % (median values 52 %). Moreover, in 4 patients, the HUMARA assay performed on pooled ECFC documented that endothelial progenitors were clonally related (Table   3 ). These findings suggest that, in this sub group of patients, endothelial progenitor cell compartment is entirely involved by the neoplastic transformation, whereas each progenitor might exhibit variable proportions of wild type and mutated alleles. The detection of SOCS gene hypermethylation and of JAK2 V617F mutation in ECFC was confirmed after expanding additional colonies for 2 or 3 passages. Finally, we rule out the possibility that the detection of MPN molecular signatures in ECFC could result from the in vivo hematopoietic-endothelial cell fusion.
Actually, we demonstrated that JAK2 V617F ECFC isolated from 3 MPN patients, evaluated at both early and late passages, do not express myeloid lineage-associated antigens (CD45, CD115, and CD11b) (Figure 2 ). Figure 5A and 5B, respectively. The percentages of mononuclear cells adherent to ECFC achieved from healthy controls and from patients are illustrated in Figure 5C (mean values of experiments performed with 2 JAK2 wild type ECFC and 4 JAK2 V617F ECFC). Actually, JAK2 V617F mutated ECFC showed a significantly higher adhesion proficiency to mononuclear cells than normal ECFC (p = 0.033).
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Finally, in order to evaluate whether the JAK2 V617F ECFC might have bound mononuclear cells in the co-culture adhesion assay, we evaluated the expression of CD45 and CD11b either at first passage after the adhesion assay and thereafter at late passages, and we found that it was always absent ( Figure 5D ).
For
Discussion
The pathophysiologic mechanisms linking JAK2 V617F mutation and the risk of thrombosis in patients with Ph-negative myeloproliferative neoplasms remain largely speculative. This study explored the hypothesis that the oncogenic lesion could hit a common endothelial and hematopoietic progenitor cell, inducing an endothelial cell dysfunction primarily responsible for the pathogenesis of the vascular damage. Either among healthy individuals or MPN patients, endothelial progenitor cells are detectable through cell culture assay only in a part of subjects and we are not aware of biological causes underlying this finding. Overall, our observations suggest that the ability to give rise to endothelial progenitor colonies does not identify a particular subset of MPN patients having different hematological or clinical peculiarities. Moreover, we show in this study that endothelial progenitor colonies isolated from MPN patients display different profiles in respect to disease-specific molecular markers.
In general population, the reduced number of circulating endothelial progenitor cells predicts future cardiovascular events 18, 26 and it is has been hypothesized that also in PV patients this mechanism could account for the increased thrombotic risk. 4 The first finding of our study is that patients with PV and ET have a level of true circulating endothelial progenitors in the normal range, whilst PMF patients have an increased number of ECFC. Our data well agree with those reported in another study employing the same rigorous cell culture procedures. 6 Dissimilar results have been reported by other groups, but the discrepancy can be explained by the use of different culture time and conditions, which evaluated hematopoietic-derived endothelial-like colonies (i.e. CFU-EC) rather than the true endothelial ones (ECFC). 4,7 Accordingly, we found that in our series of patients, and in particular in those patients with history of thrombosis, the CFU-EC level was significantly lower than in healthy subjects. In addition, the increased level of ECFC found in patients with PMF appears to be an interesting finding, considering that a defective stem cell niche would take part in the pathogenesis of this disease. 27 Actually, the development of the pathological clone in PMF is deeply influenced by alterations of the micro environmental niches: thus, the
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imbalance between endosteum and vascular niches within the bone marrow could favor proliferation of hematopoietic, mesenchymal and endothelial progenitors and their mobilization through the blood. 27 The second finding of this study is that, in a subset of patients with MPN, molecular alterations usually observed in hematopoietic cells may be detected also in the circulating endothelial progenitors. Several groups investigated the relationship between endothelial cells and hematological neoplasms, [27] [28] [29] [30] [31] [32] reported that a minority of ECFC derived from a patient with vascular thrombosis and subsequently developing JAK2 V617F PV, carried the JAK2 V617F mutation. 7 Finally, several studies well established that hemangioblasts are present in chronic myeloid leukemia and contribute to both malignant hematopoiesis and endotheliopoiesis. 28, 33 In this study the pathological involvement of endothelial progenitor compartment was explored by evaluating additional molecular markers of disease other than JAK2 or MPL mutations, such as clonality and hypermethylation of SOCS genes. We demonstrated that in a part of MPN patients molecular signatures found in hematopoietic cells (both granulocytes and CFU-EC colonies) can be detected also in endothelial progenitors. Indeed, our observations add evidences to the existence of a common hematopoietic and endothelial bi-lineage progenitor also in Ph-negative myeloproliferative neoplasms. The third finding of this study is that patients with molecular
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Actually, a significantly shorter antiproliferative therapy-free survival was observed in patients with
JAK2
V617F positive ECFC.
Finally, we found that the detection of clonality and JAK2 mutation in ECFC was associated with a thrombotic proficiency. Interestingly, these patients have at diagnosis high JAK2 allele burden and high leukocyte count, two characteristics which have been associated with an increased thrombotic risk. 34 Actually, the increased number of neutrophils have emerged as one of the most relevant factor contributing to the thrombophilic state of MPN patients and neutrophil activation occurs in these patients in parallel with the appearance of laboratory signs of hemostatic system activation. 34 Moreover, the presence of high JAK2 mutated allele burden, has been variably associated with both thrombosis and high leukocyte count. 34 Our study support the hypothesis that the pathogenesis of thrombosis in MPN may result from an endothelial progenitor cell dysfunction, as well. In fact, we show that the JAK2 mutation in endothelial cells abnormally activates the JAK/STAT pathway, which is an important regulator of the response of endothelial cells to injury 35, 36 and increases their proficiency to adhere to normal mononuclear cells. Interestingly, two of the three patient exhibiting clonal and mutated ECFC had thrombosis in the splanchnic veins (1 portal thrombosis and 1 Budd-Chiari syndrome), while a third patient presenting with massive bleeding from gastric varices, had severe portal hypertension, albeit in the absence of evident previous portal or suprahepatic veins thrombosis. Indeed, these findings well agree with previous observations that JAK2 mutated endothelial cells could be isolated from the liver of patients suffering from Budd-Chiari syndrome 8, 9 .
In conclusion, this study suggests that endothelial progenitor cell dysfunction might sustain the thrombophilic state observed in MPN patients and unravels an additional mechanism by through antiproliferative therapies could reduce the thrombotic risk. The main limit of this study resides in its retrospective nature and only prospective investigations may definitely confirm our observations. Nevertheless, the definition of molecular profile of endothelial progenitors appears to be a very 
